Fibrogenic growth factors in encapsulating peritoneal sclerosis

Nephron - Clinical Practice

Volumn 113, Issue 2, 2009, Pages

  Braun, N ^a   Reimold, F ^a   Biegger, D ^b   Fritz, P ^c   Kimmel, M ^a   Ulmer, C ^a   Alscher, M D ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b Margarete Fischer Bosch Institute

^c Department of Diagnostic Medicine

Author keywords

Encapsulating peritoneal sclerosis; Fibrosis; Growth factors; Inflammation; Peritoneal dialysis; Vascular endothelial growth factor

Indexed keywords

BINDING PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; FIBROBLAST GROWTH FACTOR BINDING PROTEIN; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; APPENDICITIS; ARTICLE; BLOOD VESSEL DIAMETER; CLINICAL ARTICLE; CONTROLLED STUDY; ENCAPSULATING PERITONEUM SCLEROSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MALE; NEPHRITIS; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCLEROSIS; TISSUE LEVEL; UPREGULATION; VASCULAR DISEASE; VASCULAR FIBROSIS;

ADULT; AGED; APPENDICITIS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PERITONEAL FIBROSIS;

EID: 67650102933     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228540     Document Type: Article

References (35)

1. Alscher DM: Principles of peritoneal dialysis. Edtna Erca J 2005; 31: 124-128; quiz 129.
2. Fenton SS, Schaubel DE, Desmeules M, et al: Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997; 30: 334-342.
3. Vonesh EF, Snyder JJ, Foley RN, Collins AJ: The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004; 66: 2389-2401.
4. Korevaar JC, Feith GW, Dekker FW, et al: Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int 2003; 64: 2222-2228.
5. Nakamoto H, Kawaguchi Y, Suzuki H: Is technique survival on peritoneal dialysis better in Japan? Perit Dial Int 2006; 26: 136-143.
6. Afthentopoulos IE, Passadakis P, Oreopoulos DG, Bargman J: Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: one center's experience and review of the literature. Adv Ren Replace Ther 1998; 5: 157-167.
7. Winnen P: Über Zuckergussdarm (peritonitis chronica fibrosa incapsulata). Brunns Beitr Klin Chir 1921; 123: 72.
8. Narayanan R, Bhargava BN, Kabra SG, Sangal BC: Idiopathic sclerosing encapsulating peritonitis. Lancet 1989;ii:127-129.
9. Kawanishi H, Kawaguchi Y, Fukui H, et al: Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44: 729-737.
10. Matsuoka T, Maeda Y, Matsuo K, Naiki Y, Tamai Y, Sakaguchi M, Hasegawa H, Funauchi M, Kanamaru A: Hepatocyte growth factor prevents peritoneal fibrosis in an animal model of encapsulating peritoneal sclerosis. J Nephrol 2008; 21: 64-73.
11. Nakamoto H: Encapsulating peritoneal sclerosis: a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005; 25 (suppl 4):S30-S38.
12. Williams JD, Craig KJ, Topley N, et al: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479.
13. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y: Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65: 1927-1936.
14. Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O: Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 2000; 11: 717-728.
15. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J: Vascular endothelial growth factors: Biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49: 1015-1026.
16. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611. (Pubitemid 39099316)
17. Frank RN: Diabetic retinopathy. N Engl J Med 2004; 350: 48-58.
18. Komatsu H, Uchiyama K, Tsuchida M, Isoyama N, Matsumura M, Hara T, Fukuda M, Kanaoka Y, Naito K: Development of a peritoneal sclerosis rat model using a continuous- infusion pump. Perit Dial Int 2008; 28: 641-647.
19. Alscher DM, Braun N, Biegger D, Fritz P: Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. Am J Kidney Dis 2007; 49: 452-461.
20. Kondo S, Kagami S, Kido H, Strutz F, Muller GA, Kuroda Y: Role of mast cell tryptase in renal interstitial fibrosis. J Am Soc Nephrol 2001; 12: 1668-1676.
21. Bird SD, Walker RJ: Mast cell histamine-induced calcium transients in cultured human peritoneal mesothelial cells. Perit Dial Int 1998; 18: 626-636.
22. Qu Z, Kayton RJ, Ahmadi P, et al: Ultrastructural immunolocalization of basic fibroblast growth factor in mast cell secretory granules: morphological evidence for bFGF release through degranulation. J Histochem Cytochem 1998; 46: 1119-1128.
23. Qu Z, Liebler JM, Powers MR, et al: Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol 1995; 147: 564-573.
24. Grutzkau A, Kruger-Krasagakes S, Baumeister H, et al: Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: Implications for the biological significance of VEGF206. Mol Biol Cell 1998; 9: 875-884.
25. Blair RJ, Meng H, Marchese MJ, et al: Human mast cells stimulate vascular tube formation: tryptase is a novel, potent angiogenic factor. J Clin Invest 1997; 99: 2691-2700.
26. Muramatsu M, Katada J, Hayashi I, Majima M: Chymase as a proangiogenic factor: a possible involvement of chymase-angiotensindependent pathway in the hamster sponge angiogenesis model. J Biol Chem 2000; 275: 5545-5552.
27. Leung JC, Chan LY, Tam KY, Tang SC, Lam MF, Cheng AS, Chu KM, Lai KN: Regulation of CCN2/CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysis. Nephrol Dial Transplant 2008;Sept 19 [Epub ahead of print].
28. Nakayama M: The plasma leak-to-response hypothesis: a working hypothesis on the pathogenesis of encapsulating peritoneal sclerosis after long-term peritoneal dialysis treatment. Perit Dial Int 2005; 25(suppl 4): S71-S76.
29. Honda K, Oda H: Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(suppl 4):S19-S29.
30. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
31. Schwartz LB, Bradford TR, Littman BH, Wintroub BU: The fibrinogenolytic activity of purified tryptase from human lung mast cells. J Immunol 1985; 135: 2762-2767.
32. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
33. Ferrara N, Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-1364.
34. Chin AI, Yeun JY: Encapsulating peritoneal sclerosis: an unpredictable and devastating complication of peritoneal dialysis. Am J Kidney Dis 2006; 47: 697-712.
35. Kawaguchi Y, Saito A, Kawanishi H, et al: Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005; 25(suppl 4):S83-S95.